https://nerdcat.org/studysummaries daily 0.75 2024-09-06 https://nerdcat.org/studysummaries/hfpef-glp1ra monthly 0.5 2024-12-04 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/7e0d872d-4a60-4839-851d-bd99df967481/Screenshot+2024-12-03+at+6.16.57%E2%80%AFPM.png Study summaries - STEP-HFpEF & SUMMIT: Incretin analogs (semaglutide & tirzepatide) in patients with HF & ejection fraction >=45% & obesity, with or without diabetes - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/2fb1e015-bdd5-4d1c-b8a9-288c9f295725/intervention.png Study summaries - STEP-HFpEF & SUMMIT: Incretin analogs (semaglutide & tirzepatide) in patients with HF & ejection fraction >=45% & obesity, with or without diabetes - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/2db027e7-3148-4bf1-8659-c336a8f29970/outcomes.png Study summaries - STEP-HFpEF & SUMMIT: Incretin analogs (semaglutide & tirzepatide) in patients with HF & ejection fraction >=45% & obesity, with or without diabetes - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://nerdcat.org/studysummaries/finearts-topcat monthly 0.5 2024-09-06 https://nerdcat.org/studysummaries/reduce-ami monthly 0.5 2024-04-16 https://nerdcat.org/studysummaries/select monthly 0.5 2024-09-10 https://nerdcat.org/studysummaries/sodium-hf monthly 0.5 2022-07-19 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/47e8e4b3-a6c8-4a6f-9744-663bfd7eac4b/sodium-hf.png Study summaries - SODIUM-HF: Sodium restriction in patients with heart failure - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://nerdcat.org/studysummaries/paragon-hf monthly 0.5 2022-05-26 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/d6c4805f-3532-4a9f-ba75-796a08c43dfb/paragon+efficacy.png Study summaries - PARAGON-HF: Sacubitril-valsartan in heart failure with ejection fraction >=45% - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1614311176983-3RB9FJK8KVHIC7JRWJF8/paragon.png Study summaries - PARAGON-HF: Sacubitril-valsartan in heart failure with ejection fraction >=45% https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/4b06d9cc-aed3-4b20-abfc-ac97db8d7db4/paragon+safety.png Study summaries - PARAGON-HF: Sacubitril-valsartan in heart failure with ejection fraction >=45% - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/cdbf2c9b-c86c-42c9-9290-14a92ac20c00/sex+lvef+paragon.png Study summaries - PARAGON-HF: Sacubitril-valsartan in heart failure with ejection fraction >=45% - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://nerdcat.org/studysummaries/emperor-preserved monthly 0.5 2021-11-24 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1631642603427-LHGX5Z37VKPX9PGU0NLV/emperor-preserved+efficacy.png Study summaries - EMPEROR-Preserved: Empagliflozin in heart failure with preserved or mildly-reduced ejection fraction - Make it stand out Efficacy outcomes https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1631638143617-8C6MG465PVBU2FQYEVXO/emperor-preserved+primary.png Study summaries - EMPEROR-Preserved: Empagliflozin in heart failure with preserved or mildly-reduced ejection fraction - Make it stand out Cumulative incidence curve for the primary composite outcome showing immediate separation of empagliflozin and placebo curves (suggesting early benefit) https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1631642606959-HU38G60JK7I3YZIF0JCM/emperor-preserved+safety.png Study summaries - EMPEROR-Preserved: Empagliflozin in heart failure with preserved or mildly-reduced ejection fraction - Make it stand out Safety outcomes https://nerdcat.org/studysummaries/galactic-hf monthly 0.5 2020-12-30 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1605560030307-YP3S98EPKQ9K83UJUS9C/image-asset.png Study summaries - GALACTIC-HF: Omecamtiv mecarbil in patients with heart failure with reduced ejection fraction Therapeutic drug monitoring protocol from final study protocol https://nerdcat.org/studysummaries/soloist-whf monthly 0.5 2020-12-18 https://nerdcat.org/studysummaries/index monthly 0.5 2020-08-31 https://nerdcat.org/studysummaries/emperor-reduced monthly 0.5 2021-09-14 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1598899466850-CTV395WX4BKVTI33N28B/SGLT2i+HF+mortality.png Study summaries - EMPEROR-Reduced: Empagliflozin in patients with heart failure with reduced ejection fraction with or without type 2 diabetes https://nerdcat.org/studysummaries/victoria monthly 0.5 2021-10-13 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1585695491506-NBML6ULVATN0YF62UO2J/RRR+HFrEF.png Study summaries - VICTORIA - Vericiguat in heart failure with reduced ejection fraction Indirect comparison of relative efficacy of different HFrEF pharmacotherapeutic options https://nerdcat.org/studysummaries/search monthly 0.5 2020-02-22 https://nerdcat.org/studysummaries/afire monthly 0.5 2020-02-22 https://nerdcat.org/studysummaries/genetics monthly 0.5 2020-02-21 https://nerdcat.org/studysummaries/twilight monthly 0.5 2020-01-23 https://nerdcat.org/studysummaries/dapa-hf monthly 0.5 2020-01-16 https://nerdcat.org/studysummaries/2019/9/4/isar-react-5 monthly 0.5 2019-09-10 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1567659329981-903TUSLPEPAOCHZ2U6EO/figure+t+vs+p.png Study summaries - ISAR-REACT 5: Ticagrelor vs prasugrel in ACS https://nerdcat.org/studysummaries/hfref-iron monthly 0.5 2021-01-05 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1609803714510-89UBYT4KUY6BFSPPZCX2/iron.png Study summaries - IV iron in HFrEF with iron deficiency https://nerdcat.org/studysummaries/augustus monthly 0.5 2019-05-22 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1558559384490-6H4ZCHRUTBPLWPA9JDW2/apixaban+vs+warfarin.png Study summaries - AUGUSTUS - Antithrombotic regimens including apixaban vs warfarin, & aspirin vs placebo, in patients with AFib plus PCI &/or ACS Outcomes at 6 months of apixaban versus warfarin in combination with P2Y12 inhibitor +/- aspirin https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1558559412837-SWRXB1OWG5CJXVM34CCI/asa+vs+placebo.png Study summaries - AUGUSTUS - Antithrombotic regimens including apixaban vs warfarin, & aspirin vs placebo, in patients with AFib plus PCI &/or ACS Outcomes at 6 months of aspirin versus placebo in combination with P2Y12 inhibitor + apixaban or warfarin https://nerdcat.org/studysummaries/tred-hf monthly 0.5 2019-02-13 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1549670254812-XGKJDIEDR5672XJGVOMT/KM.jpg Study summaries - TRED-HF - Withdrawal of HF meds in patients with recovered (non-ischemic) dilated cardiomyopathy Figure 3 from TRED-HF. Kaplan-Meier curve of time to relapsed DCM comparing discontinuation versus continuation of HF meds https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1549670395013-8UQTR0CTY67LP9QPNQM1/Venn.jpg Study summaries - TRED-HF - Withdrawal of HF meds in patients with recovered (non-ischemic) dilated cardiomyopathy Figure 4 from TRED-HF. Venn diagram breakdown of component of primary outcome met (includes all withdrawals from randomized phase + single-arm crossover phase) https://nerdcat.org/studysummaries/bridge monthly 0.5 2018-12-04 https://nerdcat.org/studysummaries/attr-act monthly 0.5 2019-01-11 https://nerdcat.org/studysummaries/reduce-it monthly 0.5 2019-04-01 https://nerdcat.org/studysummaries/linagliptin monthly 0.5 2018-11-15 https://nerdcat.org/studysummaries/dapagliflozin monthly 0.5 2018-11-15 https://nerdcat.org/studysummaries/odyssey-outcomes monthly 0.5 2019-01-11 https://nerdcat.org/studysummaries/global-leaders monthly 0.5 2018-10-03 https://nerdcat.org/studysummaries/asa-vs-rivaroxaban-vteprophylaxis monthly 0.5 2018-03-28 https://nerdcat.org/studysummaries/smart-date monthly 0.5 2018-03-20 https://nerdcat.org/studysummaries/treat monthly 0.5 2019-07-22 https://nerdcat.org/studysummaries/averroes monthly 0.5 2018-02-01 https://nerdcat.org/studysummaries/prague-18 monthly 0.5 2017-12-19 https://nerdcat.org/studysummaries/tact monthly 0.5 2017-12-07 https://nerdcat.org/studysummaries/reveal monthly 0.5 2017-10-16 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1508185456417-QXVM32MD6WIVQC7VIJN7/REVEAL.png Study summaries - REVEAL: Anacetrapib in ASCVD https://nerdcat.org/studysummaries/nesiritide monthly 0.5 2017-10-04 https://nerdcat.org/studysummaries/atlas-rivaroxaban monthly 0.5 2017-09-02 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1504254419970-NKASVM7IHUULVQ8UBHK7/ATLAS+efficacy.png Study summaries - ATLAS - Rivaroxaban in patients with a recent ACS Efficacy results https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1504254665937-GGM9HEK7EYJ8W1R7ZO5F/image-asset.png Study summaries - ATLAS - Rivaroxaban in patients with a recent ACS https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1504255735283-05NDM1UJ161A15CUYCND/TIMI+46.png Study summaries - ATLAS - Rivaroxaban in patients with a recent ACS https://nerdcat.org/studysummaries/re-dual-pci monthly 0.5 2019-03-11 https://nerdcat.org/studysummaries/cantos monthly 0.5 2017-09-02 https://nerdcat.org/studysummaries/compass monthly 0.5 2017-12-14 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1503949108004-MKGOJXXVU9HDAGW8766I/COMPASS+efficacy.png Study summaries - COMPASS - ASA + rivaroxaban (or riva alone) vs ASA alone in stable CVD Efficacy outcomes https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1505929621543-W7DDLLDHLKQ0ORACZ19H/Untitled.png Study summaries - COMPASS - ASA + rivaroxaban (or riva alone) vs ASA alone in stable CVD https://nerdcat.org/studysummaries/dose monthly 0.5 2017-09-01 https://nerdcat.org/studysummaries/doac-dosing monthly 0.5 2018-04-19 https://nerdcat.org/studysummaries/canvas monthly 0.5 2017-10-13 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1507855639393-MIO9TVX0NID1TJIDNN8R/image-asset.png Study summaries - CANVAS - Canagliflozin to prevent CV & renal events in T2DM https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1497401502361-QVELGEUNY1C5J0QM1SVQ/image-asset.png Study summaries - CANVAS - Canagliflozin to prevent CV & renal events in T2DM https://nerdcat.org/studysummaries/acs-heparin-enoxaparin-fondaparinux monthly 0.5 2017-09-01 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1496174475100-40FIEB4664VFVWDRY8CY/image-asset.png Study summaries - Heparin, enoxaparin & fondaparinux in ACS https://nerdcat.org/studysummaries/beta-blockers-cad monthly 0.5 2017-09-02 https://nerdcat.org/studysummaries/arte monthly 0.5 2017-09-02 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1495212314166-M222XKJ5J17N5D6CDWPA/image-asset.png Study summaries - ARTE - Dual versus single antiplatelet therapy after TAVI https://nerdcat.org/studysummaries/gauss-3 monthly 0.5 2017-09-01 https://nerdcat.org/studysummaries/topic monthly 0.5 2017-09-02 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1495041655788-H8VNDSTHADFEGD2KCZWA/image-asset.png Study summaries - TOPIC - Continuing ticagrelor/prasugrel vs switching to clopidogrel 1 month after ACS https://nerdcat.org/studysummaries/leader monthly 0.5 2017-09-05 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1494942946836-4Y6MZHF89DNNVNB29BAJ/image-asset.png Study summaries - LEADER - Liraglutide in diabetes with high CV risk https://nerdcat.org/studysummaries/concern monthly 0.5 2018-01-12 https://nerdcat.org/studysummaries/gemini monthly 0.5 2017-09-02 https://nerdcat.org/studysummaries/beta-blocker-side-effects monthly 0.5 2017-09-01 https://nerdcat.org/studysummaries/fourier monthly 0.5 2017-09-02 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1491319790085-NWSFLEZW59EQJ2C5GB3J/image-asset.png Study summaries - FOURIER - Evolocumab in patients with CVD https://nerdcat.org/studysummaries/testosterone-cv monthly 0.5 2017-09-01 https://nerdcat.org/studysummaries/accomplish monthly 0.5 2017-09-02 https://nerdcat.org/studysummaries/shep monthly 0.5 2017-09-01 https://nerdcat.org/studysummaries/sprint monthly 0.5 2017-09-01 https://nerdcat.org/studysummaries/fibrates monthly 0.5 2017-09-02 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1485713093413-9U1Z4GRU6JNNU4KCYCXW/image-asset.png Study summaries - Fibrates for CV prevention https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1485713290537-WWD9M47L1DUOF9O2GUZE/image-asset.png Study summaries - Fibrates for CV prevention https://nerdcat.org/studysummaries/hfref-target-dose monthly 0.5 2019-03-14 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1484422208666-G53IEXG92HKCJ0UHEWUK/image-asset.png Study summaries - RAAS inhibitor dose in HFrEF https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1484422226586-NA7HQL94ESCA0GTPDXX7/image-asset.png Study summaries - RAAS inhibitor dose in HFrEF https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1552582807181-M1A58IZPFP6JH1RMH1WC/image-asset.png Study summaries - RAAS inhibitor dose in HFrEF https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1552583148189-0BLT04XMM8KE48KRF32U/journal.pone.0212907.g002.PNG Study summaries - RAAS inhibitor dose in HFrEF https://nerdcat.org/studysummaries/invest monthly 0.5 2017-09-02 https://nerdcat.org/studysummaries/arb monthly 0.5 2017-09-28 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1483404222413-ZX6TYG50IMXI6SAOW660/image-asset.png Study summaries - ARBs vs ACEIs patients post-MI or at high risk of CVD https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1483403797594-SDDCRF35Y4R1N1534GX3/image-asset.png Study summaries - ARBs vs ACEIs patients post-MI or at high risk of CVD https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1483403811643-RG0CLVVMDLSG8NZIX5RX/image-asset.png Study summaries - ARBs vs ACEIs patients post-MI or at high risk of CVD https://nerdcat.org/studysummaries/capricorn monthly 0.5 2017-09-01 https://nerdcat.org/studysummaries/hydralazine-nitrate monthly 0.5 2017-09-01 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1482283370393-5Z8ZV3RVKSQAI79PKBRE/image-asset.png Study summaries - A-HeFT, V-HeFT, V-HeFT - Hydralazine+nitrate in HFrEF https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1482283392969-2AZ33FWO793BA69UEP68/image-asset.png Study summaries - A-HeFT, V-HeFT, V-HeFT - Hydralazine+nitrate in HFrEF https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1482283406661-1413MXICEU3J53JZIUGC/image-asset.png Study summaries - A-HeFT, V-HeFT, V-HeFT - Hydralazine+nitrate in HFrEF https://nerdcat.org/studysummaries/prosper monthly 0.5 2017-09-02 https://nerdcat.org/studysummaries/hps monthly 0.5 2017-09-02 https://nerdcat.org/studysummaries/hfref-arb monthly 0.5 2017-09-28 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1504769467778-ZVTH01UYU20DZYTDKXIW/ARB+HFrEF+PIC.png Study summaries - ARBs in HFrEF (ELITE I & II, CHARM-Alternative, CHARM-Added & Val-HeFT) https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1504769505961-8VJR5C71G3XE9HT1HA62/ARB+HFrEF+O.png Study summaries - ARBs in HFrEF (ELITE I & II, CHARM-Alternative, CHARM-Added & Val-HeFT) https://nerdcat.org/studysummaries/statin-dose monthly 0.5 2018-05-10 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1504910686050-8PLCX5DVPHB04SQW8IY3/statin+dose.png Study summaries - Statin dose & CV events https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1504910732295-PEBZ2UMJ0NMHSYFTXORO/statin+dose+outcomes.png Study summaries - Statin dose & CV events https://nerdcat.org/studysummaries/miracl monthly 0.5 2017-09-02 https://nerdcat.org/studysummaries/hfref-mra monthly 0.5 2019-05-14 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1504894256205-KQ73E71LP787SH6LX73K/MRA+PICT.png Study summaries - Mineralocorticoid receptor antagonists (MRAs) in HFrEF or post-MI LV dysfunction (EPHESUS, EMPHASIS, RALES) https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1504894297152-Q1LT8YHFPXYWKJIXTNXF/MRA+O.png Study summaries - Mineralocorticoid receptor antagonists (MRAs) in HFrEF or post-MI LV dysfunction (EPHESUS, EMPHASIS, RALES) https://nerdcat.org/studysummaries/hfpef-acei-arb monthly 0.5 2017-09-28 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1481477307525-FCE3V7XUF6EZ27UHB8O7/image-asset.png Study summaries - ACE inhibitors & ARBs in HFpEF These trials generally enrolled older individuals with clinical HF and a LVEF >40-45%. Notably, these trials excluded multiple conditions that may be classified as "HFpEF", namely valvular heart diseases such as aortic stenosis, pericardial disease and certain cardiomyopathies. https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1481477332727-O67TVTL0ZM4P55KXJZK4/image-asset.png Study summaries - ACE inhibitors & ARBs in HFpEF Due to the exclusion criteria noted above, most of the cases of HFpEF in these trials were caused by hypertension (I-PRESERVE, PEP-CHF) or ischemia (CHARM-Preserved). it is thus worth mentioning that BP was well-controlled on average at baseline in all of these trials. https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1481477344449-T4Y3I2XJPKIADPX9DQ9J/image-asset.png Study summaries - ACE inhibitors & ARBs in HFpEF https://nerdcat.org/studysummaries/ivabradine monthly 0.5 2019-03-22 https://nerdcat.org/studysummaries/trigs monthly 0.5 2017-09-01 https://nerdcat.org/studysummaries/af-chf monthly 0.5 2017-09-01 https://nerdcat.org/studysummaries/bp-lowering-high-dose-or-combo monthly 0.5 2017-09-01 https://nerdcat.org/studysummaries/warcef monthly 0.5 2017-09-02 https://nerdcat.org/studysummaries/precision monthly 0.5 2017-09-02 https://nerdcat.org/studysummaries/acei-post-mi monthly 0.5 2017-09-02 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1480358864386-M0T3N7ZYD6NHE87PLAZ4/in+all+comers.png Study summaries - ACE inhibitors post-MI (CCS-1, CONSENSUS II, GISSI-3, ISIS-4, SMILE; AIRE, SAVE, TRACE) 5 trials enrolled "all-comer" acute MI patients, regardless of the presence/absence of clinical HF or LVEF https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1480359847841-Q2XRCFZ1GH1QJ22VXDEA/image-asset.png Study summaries - ACE inhibitors post-MI (CCS-1, CONSENSUS II, GISSI-3, ISIS-4, SMILE; AIRE, SAVE, TRACE) About 20% of patients in the "all comer" trials had clinical HF. LVEF was not routinely measured & is not reported in the original trial reports https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1480358879935-KKZ4FPUDZ5CH3E36F1HV/in+hf+or+lvd.png Study summaries - ACE inhibitors post-MI (CCS-1, CONSENSUS II, GISSI-3, ISIS-4, SMILE; AIRE, SAVE, TRACE) 3 trials enrolled patients early after an MI if they had either clinical HF (AIRE) or reduced LVEF (SAVE, TRACE) for enrolment https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1480359967240-TE317O8RHABE8LZIZYKX/image-asset.png Study summaries - ACE inhibitors post-MI (CCS-1, CONSENSUS II, GISSI-3, ISIS-4, SMILE; AIRE, SAVE, TRACE) The majority of patients in the 2 trials of patients with LV dysfunction (SAVE, TRACE) did not have any clinical signs of HF at baseline despite an average LVEF ~30% https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1480360310633-EN5Q24PV6135N7P7BV0N/image-asset.png Study summaries - ACE inhibitors post-MI (CCS-1, CONSENSUS II, GISSI-3, ISIS-4, SMILE; AIRE, SAVE, TRACE) The 5 all-comer trials all evaluated outcomes in the short term, & all but CONSENSUS II (which initiated ACEI therapy as IV) demonstrated a reduction in the incidence of death +/- HF with NNT ~125-200 for death at 4-6 weeks https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1480360322198-1SNDDOZES08Q95VSA0TS/image-asset.png Study summaries - ACE inhibitors post-MI (CCS-1, CONSENSUS II, GISSI-3, ISIS-4, SMILE; AIRE, SAVE, TRACE) The trials of patients with clinical HF/LV dysfunction post-MI all evaluated outcomes beyond 1 year, with all trials demonstrating a mortality benefit that ranged from NNT 14-20 at ~1-5 y. Superficially, the greatest absolute benefit was seen in the AIRE trial, which enrolled only patients with clinical HF https://nerdcat.org/studysummaries/beta-blockers-hfref monthly 0.5 2017-09-01 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1480033189784-8S56CYJMFTDK4BSV9CRO/image-asset.png Study summaries - Beta-blockers in HFrEF (CIBIS-II, COPERNICUS, US Carvedilol HF study, MERIT-HF) https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1480033547246-XTHZD4JX2C5LX3JVTLRX/avg.png Study summaries - Beta-blockers in HFrEF (CIBIS-II, COPERNICUS, US Carvedilol HF study, MERIT-HF) https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1480033252751-BLT98FLCNLYVSTE7GHRJ/image-asset.png Study summaries - Beta-blockers in HFrEF (CIBIS-II, COPERNICUS, US Carvedilol HF study, MERIT-HF) https://nerdcat.org/studysummaries/pioneer monthly 0.5 2017-10-13 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1507855480350-73DFO1QJPO4DL6VZ6GCL/Visual+abstract+-+PIONEER.png Study summaries - PIONEER AF-PCI - Antithrombotics in patients with AF after PCI https://nerdcat.org/studysummaries/dapt-score monthly 0.5 2017-09-02 https://nerdcat.org/studysummaries/dapt monthly 0.5 2017-09-02 https://nerdcat.org/studysummaries/pegasus monthly 0.5 2017-09-02 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1478221330160-E7K9T11MN3L4BI7498JH/image-asset.png Study summaries - PEGASUS - Long-term ticagrelor in patients with prior MI https://nerdcat.org/studysummaries/plato monthly 0.5 2017-09-02 https://nerdcat.org/studysummaries/sword monthly 0.5 2017-09-01 https://nerdcat.org/studysummaries/optic monthly 0.5 2017-09-01 https://nerdcat.org/studysummaries/fh-screening monthly 0.5 2017-09-01 https://nerdcat.org/studysummaries/ldl monthly 0.5 2017-09-02 https://nerdcat.org/studysummaries/solvd monthly 0.5 2017-09-02 https://nerdcat.org/studysummaries/consensus monthly 0.5 2017-09-02 https://nerdcat.org/studysummaries/empa-reg monthly 0.5 2017-09-02 https://nerdcat.org/studysummaries/hope-europa-peace monthly 0.5 2017-09-02 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1476836710564-HQKU0D0GMH6G8FTL483E/Participants+-+HOPE%2C+EUROPA%2C+PEACE Study summaries - HOPE, EUROPA, PEACE - ACEIs in CAD & other high-risk patients without HF or LV systolic dysfunction https://nerdcat.org/studysummaries/action monthly 0.5 2017-09-02 https://nerdcat.org/studysummaries/camelot monthly 0.5 2017-09-02 https://nerdcat.org/studysummaries/corona-gissi-hf monthly 0.5 2017-09-02 https://nerdcat.org/studysummaries/osler monthly 0.5 2017-09-01 https://nerdcat.org/studysummaries/odyssey-long-term monthly 0.5 2017-09-01 https://nerdcat.org/studysummaries/coq10-statin-myalgia monthly 0.5 2017-09-02 https://nerdcat.org/studysummaries/improve-it monthly 0.5 2017-09-01 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1492451316729-72QR7E2J7B5ASVOTI96H/Visual+abstract+-+Ezetimibe.png Study summaries - IMPROVE-IT - Ezetimibe added to statin following ACS https://nerdcat.org/studysummaries/odyssey-escape monthly 0.5 2017-09-01 https://nerdcat.org/studysummaries/paradigm-hf monthly 0.5 2018-11-20 https://nerdcat.org/studysummaries/coronaryarterycalciumscore monthly 0.5 2017-09-02 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1473444788690-OCGU66RNRK2HTBM9U3Y8/image-asset.jpeg Study summaries - Testing: Coronary artery calcium to risk stratify in primary prevention Calcified LAD https://nerdcat.org/studysummaries/norstent monthly 0.5 2017-09-02 https://nerdcat.org/studysummaries/niacin monthly 0.5 2017-09-08 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1469297848425-IT5CW0QU3XI3P60K3GZV/image-asset.png Study summaries - HPS2-THRIVE - Niacin for CV prevention https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1469300378902-I7PGN32ZYBTL2UAM3GQY/image-asset.png Study summaries - HPS2-THRIVE - Niacin for CV prevention HPS2-THRIVE outcomes https://nerdcat.org/studysummaries/nimodipine monthly 0.5 2017-09-14 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1468286786000-0TQEVOW2DSWE2IM8JZGH/image-asset.png Study summaries - British aneurysm nimodipine trial: Nimodipine in subarachnoid hemorrhage https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1468535065919-UO23GVULBMXAJQLTT7AY/image-asset.png Study summaries - British aneurysm nimodipine trial: Nimodipine in subarachnoid hemorrhage https://nerdcat.org/studysummaries/atach-2 monthly 0.5 2017-09-01 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1466279344635-USFC06JHUSG1LMDTV95Z/image-asset.png Study summaries - ATACH-2 - Intensive BP lowering in ICH https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1466191457834-I5K0HHGVI9QMSTSL97NO/image-asset.png Study summaries - ATACH-2 - Intensive BP lowering in ICH ATACH-2 Outcomes https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1466191682084-DRTXQNC4M0WUA9T9HD0L/image-asset.png Study summaries - ATACH-2 - Intensive BP lowering in ICH ATACH-2 organ-specific SAEs https://nerdcat.org/studysummaries/eagles monthly 0.5 2017-09-14 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1466655788253-BJMWKEE0KAW14CRJ6EK0/image-asset.png Study summaries - EAGLES - Efficacy & neuropsychiatric safety of smoking cessation products (varenicline, bupropion, nicotine patch) https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1466618689178-SPMYR6C51283PVBS53W9/image-asset.png Study summaries - EAGLES - Efficacy & neuropsychiatric safety of smoking cessation products (varenicline, bupropion, nicotine patch) EAGLES trial outcomes in patients WITH psychiatric disorder https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1466618763402-KBQJWUJR1419916PKRR7/image-asset.png Study summaries - EAGLES - Efficacy & neuropsychiatric safety of smoking cessation products (varenicline, bupropion, nicotine patch) EAGLES trial outcomes in patients withOUT psychiatric disorder https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1466616624313-ZPGONFFFSCJ5D4HVD122/image-asset.png Study summaries - EAGLES - Efficacy & neuropsychiatric safety of smoking cessation products (varenicline, bupropion, nicotine patch) NNT for abstinence from smoking in EAGLES trial https://nerdcat.org/studysummaries/cogent monthly 0.5 2017-09-14 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1465440668732-HNBFZG959JZ9Z8JGBIS4/image-asset.png Study summaries - COGENT - PPI added to DAPT in patients after ACS/PCI https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1465409306330-D07B201QDWJ7763M5D5M/image-asset.png Study summaries - COGENT - PPI added to DAPT in patients after ACS/PCI Outcomes in COGENT trial https://nerdcat.org/studysummaries/proact monthly 0.5 2018-07-31 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1464665328269-2RPU7EARZ8Y7Q4KPRFPT/image-asset.png Study summaries - PROACT - Reduced INR goal (1.5-2) with On-X mechanical aortic valve https://nerdcat.org/studysummaries/socrates monthly 0.5 2017-09-14 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1463696869087-7QHECAQDWRX1GWY0M7GA/image-asset.png Study summaries - SOCRATES - Ticagrelor vs aspirin in minor ischemic stroke or TIA Outcomes in SOCRATES https://nerdcat.org/studysummaries/tmp-smx monthly 0.5 2017-09-14 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1462932408864-S8Q97HQUPJ4PB7OF63IM/image-asset.png Study summaries - Trimethoprim-sulfamethoxazole for uncomplicated skin abscess https://nerdcat.org/studysummaries/hope-3-statin monthly 0.5 2017-09-14 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1462673605798-H7ACTAD5HGA2FIYTM9HH/image-asset.png Study summaries - HOPE-3 (statin) https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1462672983326-8N6SZEC1D7TONFR5JW6C/image-asset.png Study summaries - HOPE-3 (statin) Outcomes in HOPE-3 statin trial https://nerdcat.org/studysummaries/hope-3-bp monthly 0.5 2017-09-14 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1462422576870-XN0TWVNMKG0QD4X3CEOQ/image-asset.png Study summaries - HOPE-3 (BP lowering) https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1462297643512-HQEITO6RV1CD1UF62TDW/image-asset.png Study summaries - HOPE-3 (BP lowering) Outcomes in HOPE-3 BP-lowering trial https://nerdcat.org/studysummaries/category/Ventricular+arrhythmias monthly 0.5 https://nerdcat.org/studysummaries/category/Hypertension monthly 0.5 https://nerdcat.org/studysummaries/category/FH monthly 0.5 https://nerdcat.org/studysummaries/category/AF monthly 0.5 https://nerdcat.org/studysummaries/category/VTE monthly 0.5 https://nerdcat.org/studysummaries/category/Dyslipidemia monthly 0.5 https://nerdcat.org/studysummaries/category/HFpEF monthly 0.5 https://nerdcat.org/studysummaries/category/Overweight%2Fobesity monthly 0.5 https://nerdcat.org/studysummaries/category/HFrEF monthly 0.5 https://nerdcat.org/studysummaries/category/HFmrEF monthly 0.5 https://nerdcat.org/studysummaries/category/Valvular+heart+disease monthly 0.5 https://nerdcat.org/studysummaries/category/ACS monthly 0.5 https://nerdcat.org/studysummaries/category/CAD+%2B%2F-+PCI monthly 0.5 https://nerdcat.org/studysummaries/category/SAH monthly 0.5 https://nerdcat.org/studysummaries/category/ID monthly 0.5 https://nerdcat.org/studysummaries/category/Diabetes monthly 0.5 https://nerdcat.org/studysummaries/tag/icosapent+ethyl+%2F+omega-3+fatty+acids monthly 0.5 https://nerdcat.org/studysummaries/tag/SGLT2+inhibitors+%28gliflozins%29 monthly 0.5 https://nerdcat.org/studysummaries/tag/DPP-4+inhibitors monthly 0.5 https://nerdcat.org/studysummaries/tag/Vericiguat monthly 0.5 https://nerdcat.org/studysummaries/tag/Ezetimibe monthly 0.5 https://nerdcat.org/studysummaries/tag/PPI monthly 0.5 https://nerdcat.org/studysummaries/tag/Semaglutide monthly 0.5 https://nerdcat.org/studysummaries/tag/GLP1RA monthly 0.5 https://nerdcat.org/studysummaries/tag/Sacubitril monthly 0.5 https://nerdcat.org/studysummaries/tag/CCBs monthly 0.5 https://nerdcat.org/studysummaries/tag/Antiarrhythmics monthly 0.5 https://nerdcat.org/studysummaries/tag/Mineralocorticoid+receptor+antagonists+%28MRAs%29 monthly 0.5 https://nerdcat.org/studysummaries/tag/Smoking+cessation monthly 0.5 https://nerdcat.org/studysummaries/tag/Labs+%26+tests monthly 0.5 https://nerdcat.org/studysummaries/tag/Coenzyme+Q10 monthly 0.5 https://nerdcat.org/studysummaries/tag/NSAIDs monthly 0.5 https://nerdcat.org/studysummaries/tag/Diuretics monthly 0.5 https://nerdcat.org/studysummaries/tag/Hydralazine-nitrate monthly 0.5 https://nerdcat.org/studysummaries/tag/Statins monthly 0.5 https://nerdcat.org/studysummaries/tag/CETP+inhibitors monthly 0.5 https://nerdcat.org/studysummaries/tag/Pharmacogenomics monthly 0.5 https://nerdcat.org/studysummaries/tag/PCSK9+inhibitors monthly 0.5 https://nerdcat.org/studysummaries/tag/P2Y12+inhibitors monthly 0.5 https://nerdcat.org/studysummaries/tag/Ivabradine monthly 0.5 https://nerdcat.org/studysummaries/tag/non-pharmacological monthly 0.5 https://nerdcat.org/studysummaries/tag/Duration monthly 0.5 https://nerdcat.org/studysummaries/tag/Beta-blockers monthly 0.5 https://nerdcat.org/studysummaries/tag/Heparin+%26+other+parenteral+anticoagulants monthly 0.5 https://nerdcat.org/studysummaries/tag/Warfarin+%26+DOACs monthly 0.5 https://nerdcat.org/studysummaries/tag/Niacin monthly 0.5 https://nerdcat.org/studysummaries/tag/Testosterone monthly 0.5 https://nerdcat.org/studysummaries/tag/Antiplatelets monthly 0.5 https://nerdcat.org/studysummaries/tag/iron monthly 0.5 https://nerdcat.org/studysummaries/tag/Fibrates monthly 0.5 https://nerdcat.org/studysummaries/tag/ARBs monthly 0.5 https://nerdcat.org/studysummaries/tag/ACE+inhibitors monthly 0.5 https://nerdcat.org/studysummaries/tag/Liraglutide monthly 0.5 https://nerdcat.org/studysummaries/tag/Natriuretic+peptides monthly 0.5 https://nerdcat.org/graphical-study-summaries daily 0.75 2021-09-13 https://nerdcat.org/graphical-study-summaries/2021/9/13/east-afnet-4-early-rhythm-control-in-af monthly 0.5 2021-09-13 https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1631577190559-HO6FMTQF5PKTQLCPZQQ4/EAST-AFNET+4+-+Early+rhythm+control+in+AF_Page_1.png Graphical study summaries - EAST-AFNET 4 - Early rhythm control in AF - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/56a0651bbe7b96af3e170173/1631577236200-3YS4IR9U7FG3DCBD064K/EAST-AFNET+4+-+Early+rhythm+control+in+AF_Page_2.png Graphical study summaries - EAST-AFNET 4 - Early rhythm control in AF - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://nerdcat.org/about daily 0.75 2020-04-24 https://nerdcat.org/nerdcats daily 1.0 2022-01-14 https://nerdcat.org/ebm-resources daily 0.75 2025-05-13 https://nerdcat.org/physical-exam-for-pharmacists daily 0.75 2016-12-02 https://nerdcat.org/share-hf-faq daily 0.75 2026-03-30